The laboratory focuses on Glioblastoma (GBM) which is the most common and aggressive form of adult brain cancer. GBM kills approximately 1200 people per year in Australia. Survival rates are very poor with a median survival of approximately 15 months. Meaningful advancements in patient treatment and survival have not changed for decades. New and better treatment therapies are urgently needed.
The laboratory also studies a number of paediatric brain cancers including medulloblastoma and an incurable form of brain stem glioma called diffuse intrinsic pontine glioma (DIPG). Our goal is to design therapies that specifically treat the tumour while keeping the healthy developing brain intact.
QCell is a high quality, well-characterised panel of primary brain cancer cell line models for academic and commercial use. For further information, please click here:
Sid Faithfull and his wife, Christine Sadler, have been major supporters of QIMR Berghofer since 2013. Tragically, Sid passed away from brain cancer in 2014. In June 2018 our lab was renamed as the Sid Faithfull Brain Cancer Laboratory to honour Sid and the valuable contributions of his family. Christine and Sid’s visionary investment enables us to build capacity through innovation, obtain vital resources and instigate trials that ultimately lead to better treatments and improved quality of life for people suffering brain cancer.
Sid grew up in the Far North of Australia and experienced a wide range of interesting professions before finding his niche in maritime logistical support. A visionary in many ways, Sid realised opportunities and had the courage of his convictions to drive change. He was a quiet achiever; an entrepreneur who created Australia’s largest privately owned shipping company, Sea Swift.
In honour of Sid, sharing his vision and desire to drive change and innovation, Christine, Arran, Bradley, Jessie and their families have enabled us to continue to expand our world class research and support the next generation of talented young scientists.
We gratefully acknowledge support from the following: